SCHEMBL4766733

SCHEMBL4766733

CCCC[Sn](CCCC)(CCCC)c1ccc(C(=O)N(C)CCC)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 5/20 0.42
ALDH1A1 P00352 1/20 0.41
ACACB O00763 1/20 0.41
EGFR P00533 2/20 0.40
ERBB2 P04626 2/20 0.40
PDK2 Q15119 2/20 0.39
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
MLYCD O95822 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9596990 0.86 HPGD (0.44) ALDH1A1EGFRERBB2GAAHPGD
SCHEMBL4770283 0.80 MLYCD (0.40) NAMPTALDH1A1GAAHPGDHDAC6
SCHEMBL6288870 0.79 BDKRB2 (0.44) ALDH1A1HPGDCNR2
SCHEMBL3855292 0.77 LMNA (0.37) NAMPTALDH1A1PDK2GAAHPGD
SCHEMBL28435445 0.77 KMT2A (0.44) GAAHPGD
SCHEMBL2480571 0.77 RARB (0.50) ALDH1A1
SCHEMBL8979697 0.76 MAPK1 (0.46) ALDH1A1
SCHEMBL11133367 0.75 HDAC6 (0.55) NAMPTALDH1A1EGFRERBB2HDAC6
SCHEMBL21077963 0.75 CDK4 (0.50) NAMPTALDH1A1ACACBEGFRERBB2
SCHEMBL4495603 0.75 ESRRG (0.56) NAMPTALDH1A1ACACBEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 NAMPT 2297/4885ALDH1A1 2989/4885ACACB 4365/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 NAMPT 4470/4885ALDH1A1 1071/4885ACACB 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.